Glenmark Pharmaceuticals Limited (IN:GLENMARK)
:GLENMARK
Want to see IN:GLENMARK full AI Analyst Report?
Top Page
Glenmark Pharmaceuticals Limited
(GLENMARK)
Select Model
Select Model
Rating:60Neutral
Price Target:
₹2,311.00
▲(11.86% Upside)
Action:Reiterated
Date:06/02/26
The score is driven primarily by improved financial performance (profitability rebound and a significantly de-risked balance sheet), offset by historical earnings/cash-flow volatility. Technicals are mixed/neutral, and valuation is a key headwind due to the high P/E and minimal dividend yield.
Positive Factors
De-risked balance sheet
A materially lower debt-to-equity (~0.06 in FY2026) meaningfully reduces financial risk and interest burden, increasing flexibility to fund R&D, capex or M&A from internal resources. This durability improves solvency through industry cycles and supports strategic choices.
Negative Factors
Inconsistent cash generation
Volatile operating and free cash flows — including negative OCF/FCF in FY2024–FY2025 and a FY2026 FCF decline — weaken the company’s ability to reliably fund capex, dividends or bolt-on deals. Persistent inconsistency raises refinancing and operational risk.
Read all positive and negative factors
Positive Factors
Negative Factors
De-risked balance sheet
A materially lower debt-to-equity (~0.06 in FY2026) meaningfully reduces financial risk and interest burden, increasing flexibility to fund R&D, capex or M&A from internal resources. This durability improves solvency through industry cycles and supports strategic choices.
Read all positive factors
Glenmark Pharmaceuticals Limited (GLENMARK) vs. iShares MSCI India ETF (INDA)
Market Cap
₹608.65B
Dividend Yield0.24%
Average Volume (3M)28.97K
Price to Earnings (P/E)44.3
Beta (1Y)0.59
Revenue Growth27.48%
EPS Growth30.05%
CountryIN
Employees14,989
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)35.78
Shares Outstanding282,200,800
10 Day Avg. Volume44,119
30 Day Avg. Volume28,971
Financial Highlights & Ratios
PEG Ratio1.47
Price to Book (P/B)5.72
Price to Sales (P/S)3.54
P/FCF Ratio30.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)84.62
Revenue Forecast (FY)₹166.82B
Glenmark Pharmaceuticals Limited Business Overview & Revenue Model
Company Description
Glenmark Pharmaceuticals Limited, including its associated entities, is a global pharmaceutical company specializing in the research, development, production, and marketing of medicinal products. Its operational reach spans India, North America, L...
How the Company Makes Money
Glenmark primarily makes money by selling pharmaceutical products and related services across geographies, with revenue generated from (1) finished-dosage formulations sold under branded and/or generic portfolios in key markets, (2) sales of activ...
Glenmark Pharmaceuticals Limited Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
80
Positive
Cash Flow
58
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 159.26B | 169.83B | 133.63B | 126.45B | 116.56B | 123.05B |
| Gross Profit | 91.81B | 80.84B | 88.38B | 80.66B | 72.45B | 77.57B |
| EBITDA | 25.04B | 27.67B | 21.68B | 18.30B | 14.29B | 19.12B |
| Net Income | 10.10B | 13.62B | 10.47B | -15.02B | 2.97B | 9.42B |
Balance Sheet | ||||||
| Total Assets | 190.02B | 199.08B | 160.50B | 143.59B | 193.72B | 170.83B |
| Cash, Cash Equivalents and Short-Term Investments | 29.58B | 14.01B | 17.12B | 16.64B | 11.73B | 14.43B |
| Total Debt | 12.24B | 5.94B | 24.73B | 12.31B | 46.08B | 39.62B |
| Total Liabilities | 94.20B | 93.96B | 72.00B | 65.11B | 95.32B | 76.45B |
| Stockholders Equity | 95.82B | 105.12B | 88.49B | 78.48B | 94.74B | 90.87B |
Cash Flow | ||||||
| Free Cash Flow | 23.35B | 19.41B | -15.77B | -11.64B | 176.29M | 3.19B |
| Operating Cash Flow | 28.36B | 32.99B | -8.28B | -2.65B | 6.25B | 11.09B |
| Investing Cash Flow | -5.02B | -13.25B | 20.94M | 45.44B | -5.28B | -3.33B |
| Financing Cash Flow | -14.90B | -25.21B | 7.87B | -39.06B | -774.56M | -5.20B |
Glenmark Pharmaceuticals Limited Technical Analysis
Negative
2065.95
Price Trends
2267.00
Negative
2165.88
Negative
2061.12
Positive
Market Momentum
-41.20
Positive
38.68
Neutral
25.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:GLENMARK, the sentiment is Negative. The current price of 2065.95 is below the 20-day moving average (MA) of 2228.60, below the 50-day MA of 2267.00, and above the 200-day MA of 2061.12, indicating a neutral trend. The MACD of -41.20 indicates Positive momentum. The RSI at 38.68 is Neutral, neither overbought nor oversold. The STOCH value of 25.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:GLENMARK.
Glenmark Pharmaceuticals Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | ₹1.04T | 19.47 | ― | 0.57% | 23.12% | 62.27% | |
69 Neutral | ₹639.60B | 27.79 | ― | 0.80% | 13.48% | 6.18% | |
69 Neutral | ₹372.89B | 35.98 | ― | 2.16% | 1.93% | 11.69% | |
68 Neutral | ₹810.28B | 23.57 | ― | 0.33% | 6.08% | 0.77% | |
60 Neutral | ₹608.65B | 44.28 | ― | 0.24% | 27.48% | 30.05% | |
56 Neutral | ₹674.13B | 170.22 | ― | 0.12% | 10.91% | -67.33% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:GLENMARK
Glenmark Pharmaceuticals Limited
2,135.35
479.27
28.94%
IN:ALKEM
Alkem Laboratories Ltd.
5,346.85
588.51
12.37%
IN:AUROPHARMA
Aurobindo Pharma Ltd
1,422.10
319.19
28.94%
IN:BIOCON
Biocon Limited
411.70
70.01
20.49%
IN:GLAXO
GlaxoSmithKline Pharmaceuticals Limited
2,198.85
-1,004.48
-31.36%
IN:LUPIN
Lupin Limited
2,266.80
325.16
16.75%
Glenmark Pharmaceuticals Limited Corporate Events
Glenmark to Shift Nebulizer IP to Subsidiary in Strategic Respiratory Push
May 29, 2026
Glenmark Pharmaceuticals has approved the transfer of its nebulizer brands and intellectual property portfolio to its wholly owned subsidiary, Glenmark Healthcare Limited, for a cash consideration of Rs. 223 crore, based on an independent valuatio...
Glenmark’s U.S. Unit Reaches $29.6 Million Antitrust Settlement With State Attorneys General
May 23, 2026
Glenmark Pharmaceuticals’ U.S. subsidiary, Glenmark Pharmaceuticals Inc., USA, has agreed to settle long-running antitrust and consumer protection litigation brought by 46 state attorneys general over alleged price-fixing and anti-competitiv...
Glenmark Launches Low-Cost Semaglutide GLIPIQ in India to Expand Diabetes Care
Mar 20, 2026
Glenmark Pharmaceuticals has launched GLIPIQ (semaglutide) in India for the management of Type 2 diabetes, aiming to make GLP-1 therapy significantly more affordable and accessible. The product, approved by the Central Drugs Standard Control Organ...
Glenmark launches low-cost semaglutide GLIPIQ in India to widen diabetes care access
Mar 20, 2026
Glenmark Pharmaceuticals has launched GLIPIQ (semaglutide) in India for the management of Type 2 Diabetes Mellitus, positioning it as a significantly more affordable GLP-1 therapy to widen access to advanced injectable treatment. Approved by the C...
Glenmark Wins U.S. FDA Nod and 180-Day Exclusivity for Generic FloVent Inhaler
Mar 4, 2026
Glenmark Specialty SA, a unit of Glenmark Pharmaceuticals, has received final U.S. FDA approval for its Fluticasone Propionate Inhalation Aerosol USP, 44 mcg per actuation, deemed bioequivalent and therapeutically equivalent to GlaxoSmithKlineR...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.